Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 3/5 criteria met. Data as of 17/09/2026.
- ✅ Price trend passed
- ✅ Growth passed
- ❌ Debt failed
- ✅ P/E passed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 76.77%
Price change 2019 → 2020: 7.73%
Price change 2020 → 2021: 39.23%
Price change 2021 → 2022: -34.88%
Price change 2022 → 2023: 12.40%
Price change 2023 → 2024: -28.99%
Price change 2024 → 2025: 9.09%
Price change 2025 → 2026: 10.91%
Price change 2026 (year to date): 12.62%
Financial growth
Revenue CAGR (8 years): 16.69%
Earnings CAGR (8 years): 7.84%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.74
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 6.39
P/E < 25.0 (maximum threshold).
Correction (6 months)
Current correction: 5.43% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ARG.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Argan S.A. | 6.5 | 0.74 | +13.5 % | 🔒 |
| Altarea SCA | 47.8 | 1.57 | +8.1 % | – |
| Carmila S.A. | 6.8 | 0.80 | +44.6 % | – |
| Icade S.A. | – | 1.13 | +0.1 % | – |
| Mercialys | 16.3 | 2.94 | +3.1 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|